Pentostatin, cyclophosphamide and rituximab is a safe and effective treatment in patients with Waldenström's Macroglobulinemia.

Leukemia & lymphoma

PubMedID: 24724778

Herth I, Hensel M, Rieger M, Horstmann K, Hiddemann W, Dreyling M, Koniczek S, Witzens-Harig M, Ho AD. Pentostatin, cyclophosphamide and rituximab is a safe and effective treatment in patients with Waldenström's Macroglobulinemia. Leuk Lymphoma. 2014;.
Waldenström's Macroglobulinemia (WM) is an indolent lymphoma and is responsive to therapy regimens containing alkylating agents, purine analogues and rituximab if treatment becomes necessary. We initiated a multi-center phase II trial to determine the safety and efficacy of a regimen containing pentostatin, cyclophosphamide and rituximab (PER) in patients with WM. Between May 2005 and December 2010 twenty-five patients with WM were included in the study. Twenty-one patients received PER as first-line therapy. In these patients, two-year progression-free survival was 83.6% and two-year overall survival was 100%. Thirteen patients (52%) started with the rituximab maintenance therapy. In these patients, the two-year progression-free survival was 91.67% and two-year overall survival was 100%. We have provided evidence that PER is a safe and effective regimen for WM. Although rituximab maintenance therapy after PER seemed to induce a better long term outcome, this study was not powered to address this issue.